{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:09:23Z","timestamp":1777468163413,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T00:00:00Z","timestamp":1271030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/bf03346679","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T13:20:46Z","timestamp":1395926446000},"page":"730-738","source":"Crossref","is-referenced-by-count":10,"title":["Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation"],"prefix":"10.1007","volume":"33","author":[{"given":"P.","family":"Comeglio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. K.","family":"Chavalmane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Fibbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Marchetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Penna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Vignozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. B.","family":"Vannelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Adorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,12]]},"reference":[{"key":"BF03346679_CR1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/pr.56.4.4","volume":"56","author":"KE Andersson","year":"2004","unstructured":"Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004, 56: 581\u2013631.","journal-title":"Pharmacol Rev"},{"key":"BF03346679_CR2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ncpuro1060","volume":"5","author":"AK Patel","year":"2008","unstructured":"Patel AK, Chapple CR. Medical management of lower urinary tract symptoms in men: current treatment and future approaches. Nat Clin Pract Urol 2008, 5: 211\u20139.","journal-title":"Nat Clin Pract Urol"},{"key":"BF03346679_CR3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0031-6997(25)00442-9","volume":"45","author":"KE Anderson","year":"1993","unstructured":"Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993, 45: 253\u2013308.","journal-title":"Pharmacol Rev"},{"key":"BF03346679_CR4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00345-001-0237-0","volume":"19","author":"KE Andersson","year":"2002","unstructured":"Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002, 19: 390\u20136.","journal-title":"World J Urol"},{"key":"BF03346679_CR5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/nau.20071","volume":"23","author":"H Nakai","year":"2004","unstructured":"Nakai H, Yamanishi T, Yasuda K, Kitahara S, Suzuki T. Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia. Neurourol Urodyn 2004, 23: 618\u201322.","journal-title":"Neurourol Urodyn"},{"key":"BF03346679_CR6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00345-005-0019-1","volume":"23","author":"P Hedlund","year":"2005","unstructured":"Hedlund P. Nitric oxide\/cGMP-mediated effects in the outflow region of the lower urinary tract\u2014is there a basis for pharmacological targeting of cGMP? World J Urol 2005, 23: 362\u20137.","journal-title":"World J Urol"},{"key":"BF03346679_CR7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1464-410X.1997.00252.x","volume":"80","author":"WP Witjes","year":"1997","unstructured":"Witjes WP, Aarnink RG, Ezz-el-Din K, Wijkstra H, Debruyne EM, de la Rosette JJ. The correlation between prostate volume, transition zone volume, transition zone index and clinical and urodynamic investigations in patients with lower urinary tract symptoms. Br J Urol 1997, 80: 84\u201390.","journal-title":"Br J Urol"},{"key":"BF03346679_CR8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/pros.10084","volume":"52","author":"G Kramer","year":"2002","unstructured":"Kramer G, Steiner GE, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002, 52: 43\u201358.","journal-title":"Prostate"},{"key":"BF03346679_CR9","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.eururo.2006.12.011","volume":"51","author":"G Kramer","year":"2007","unstructured":"Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007, 51: 1202\u201316.","journal-title":"Eur Urol"},{"key":"BF03346679_CR10","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.eururo.2007.06.038","volume":"52","author":"A Sciarra","year":"2007","unstructured":"Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: evidence fora link? Eur Urol 2007, 52: 964\u201372.","journal-title":"Eur Urol"},{"key":"BF03346679_CR11","first-page":"1","volume":"1","author":"JC Nickel","year":"1994","unstructured":"Nickel JC. Prostatic inflammation in benign prostatic hyperplasia \u2014 the third component? Can J Urol 1994, 1: 1\u20134.","journal-title":"Can J Urol"},{"key":"BF03346679_CR12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ucl.2007.09.012","volume":"35","author":"JC Nickel","year":"2008","unstructured":"Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 2008, 35: 109\u201315.","journal-title":"Urol Clin North Am"},{"key":"BF03346679_CR13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1530\/eje.0.1500591","volume":"150","author":"C Crescioli","year":"2004","unstructured":"Crescioli C, Ferruzzi P, Caporali A, et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 2004, 150: 591\u2013603.","journal-title":"Eur J Endocrinol"},{"key":"BF03346679_CR14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1210\/jc.2004-1496","volume":"90","author":"C Crescioli","year":"2005","unstructured":"Crescioli C, Morelli A, Adorini L, et al. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005, 90: 962\u201372.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346679_CR15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/pros.20463","volume":"67","author":"A Morelli","year":"2007","unstructured":"Morelli A, Vignozzi L, Filippi S, et al. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA\/Rho kinase signaling in rat and human bladder. Prostate 2007, 67: 234\u201347.","journal-title":"Prostate"},{"key":"BF03346679_CR16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF03344169","volume":"29","author":"M Maggi","year":"2006","unstructured":"Maggi M, Crescioli C, Morelli A, Colli E, Adorini L. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). J Endocrinol Invest 2006, 29: 665\u201374.","journal-title":"J Endocrinol Invest"},{"key":"BF03346679_CR17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jsbmb.2006.12.065","volume":"103","author":"L Adorini","year":"2007","unstructured":"Adorini L, Penna G, Amuchastegui S, et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 2007, 103: 689\u201393.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BF03346679_CR18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/pros.20896","volume":"69","author":"G Penna","year":"2009","unstructured":"Penna G, Fibbi B, Amuchastegui S, et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA\/Rho kinase and NF-kappaB pathways. Prostate 2009, 69: 480\u201393.","journal-title":"Prostate"},{"key":"BF03346679_CR19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ncprheum0855","volume":"4","author":"L Adorini","year":"2008","unstructured":"Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008, 4: 404\u201312.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"BF03346679_CR20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.bjp.0705109","volume":"138","author":"A Wibberley","year":"2003","unstructured":"Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol 2003, 138: 757\u201366.","journal-title":"Br J Pharmacol"},{"key":"BF03346679_CR21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.103.058255","volume":"308","author":"M Fleichman","year":"2004","unstructured":"Fleichman M, Schneider T, Fetscher C, Michel MC. Signal transduction underlying carbachol-induced contraction of rat urinary bladder. II. Protein kinases. J Pharmacol Exp Ther 2004, 308: 54\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF03346679_CR22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1124\/jpet.103.063735","volume":"309","author":"T Schneider","year":"2004","unstructured":"Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 2004, 309: 1148\u201353.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF03346679_CR23","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/01.ju.0000130419.32165.6b","volume":"172","author":"R Takahashi","year":"2004","unstructured":"Takahashi R, Nishimura J, Hirano K, Seki N, Naito S, Kanaide H. Ca2+ sensitization in contraction of human bladder smooth muscle. J Urol 2004, 172: 748\u201352.","journal-title":"J Urol"},{"key":"BF03346679_CR24","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0016-5085(03)00283-X","volume":"124","author":"JP Segain","year":"2003","unstructured":"Segain JP, Raingeard de la Bl\u00e9ti\u00e8re D, Sauzeau V, et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn\u2019s disease and experimental colitis. Gastroenterology 2003, 124: 1180\u20137.","journal-title":"Gastroenterology"},{"key":"BF03346679_CR25","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1002\/art.23986","volume":"58","author":"Y He","year":"2008","unstructured":"He Y, Xu H, Liang L, et al. Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum 2008, 58: 3366\u201376.","journal-title":"Arthritis Rheum"},{"key":"BF03346679_CR26","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/sj.bjp.0705551","volume":"140","author":"A Masamune","year":"2003","unstructured":"Masamune A, Kikuta K, Satoh M, Satoh K, Shimosegawa T. Rho kinase inhibitors block activation of pancreatic stellate cells. Br J Pharmacol 2003, 140: 1292\u2013302.","journal-title":"Br J Pharmacol"},{"key":"BF03346679_CR27","first-page":"69","volume":"74","author":"JA Low","year":"1989","unstructured":"Low JA, Armstrong JB, Mauger GM. The unstable urethra in the female. Obstet Gynecol 1989, 74: 69\u201374.","journal-title":"Obstet Gynecol"},{"key":"BF03346679_CR28","first-page":"1","volume":"42","author":"CG Roehrborn","year":"2002","unstructured":"Roehrborn CG, McConnell JD, Saltzman B, et al;PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 2002, 42: 1\u20136.","journal-title":"Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol"},{"key":"BF03346679_CR29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0022-5347(05)66102-2","volume":"166","author":"A Tubaro","year":"2001","unstructured":"Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol 2001, 166: 172\u20136.","journal-title":"J Urol"},{"key":"BF03346679_CR30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1464-410X.2003.04072.x","volume":"91","author":"M Gacci","year":"2003","unstructured":"Gacci M, Bartoletti R, Figlioli S, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int 2003, 91: 196\u2013200.","journal-title":"BJU Int"},{"key":"BF03346679_CR31","first-page":"2576","volume":"85","author":"C Crescioli","year":"2000","unstructured":"Crescioli C, Maggie M, Vannelli GB, et al. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab 2000, 85: 2576\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346679_CR32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1743-6109.2008.01057.x","volume":"6","author":"A Morelli","year":"2009","unstructured":"Morelli A, Chavalmane AK, Filippi S, et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA\/Rho-kinase signaling hyperactivation. J Sex Med 2009, 6: 91\u2013106.","journal-title":"J Sex Med"},{"key":"BF03346679_CR33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbrc.2007.12.090","volume":"369","author":"F Matsumura","year":"2008","unstructured":"Matsumura F, Hartshorne DJ. Myosin phosphatase target subunit: Many roles in cell function. Biochem Biophys Res Commun 2008, 369: 149\u201356.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF03346679_CR34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/mol.61.2.277","volume":"61","author":"Y Kawanabe","year":"2002","unstructured":"Kawanabe Y, Okamoto Y, Nozaki K, Hashimoto N, Miwa S, Masaki T. Molecular mechanism for endothelin-1-induced stress-fiber formation: analysis of G proteins using a mutant endothelin(A) receptor. Mol Pharmacol 2002, 61: 277\u201384.","journal-title":"Mol Pharmacol"},{"key":"BF03346679_CR35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.atherosclerosis.2008.03.006","volume":"199","author":"ME Ivey","year":"2008","unstructured":"Ivey ME, Osman N, Little PJ. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 2008, 199: 237\u201347.","journal-title":"Atherosclerosis"},{"key":"BF03346679_CR36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-642-55580-0_2","volume":"164","author":"C Carlberg","year":"2003","unstructured":"Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res 2003, 164: 29\u201342.","journal-title":"Recent Results Cancer Res"},{"key":"BF03346679_CR37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jsbmb.2006.12.095","volume":"103","author":"AF Gombart","year":"2007","unstructured":"Gombart AF, O\u2019Kelly J, Saito T, Koeffler HP. Regulation of the CAMP gene by 1,25(OH)2D3 in various tissues. J Steroid Biochem Mol Biol 2007, 103: 552\u20137.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BF03346679_CR38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.rcl.2006.07.007","volume":"44","author":"A Mong","year":"2006","unstructured":"Mong A, Bellah R. Imaging the pediatric prostate. Radiol Clin North Am 2006, 44: 749\u201356.","journal-title":"Radiol Clin North Am"},{"key":"BF03346679_CR39","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00247-007-0495-0","volume":"37","author":"TL Levin","year":"2007","unstructured":"Levin TL, Han B, Little BP. Congenital anomalies of the male urethra. Pediatr Radiol 2007, 37: 851\u201362.","journal-title":"Pediatr Radiol"},{"issue":"6","key":"BF03346679_CR40","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/nau.20475","volume":"26","author":"GJ Christ","year":"2007","unstructured":"Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn 2007, 26 (6 Suppl): 948\u201354.","journal-title":"Neurourol Urodyn"},{"key":"BF03346679_CR41","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1152\/physrev.00023.2003","volume":"83","author":"AP Somlyo","year":"2003","unstructured":"Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003, 83: 1325\u201358.","journal-title":"Physiol Rev"},{"key":"BF03346679_CR42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0165-6147(00)01596-0","volume":"22","author":"Y Fukata","year":"2001","unstructured":"Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001, 22: 32\u20139.","journal-title":"Trends Pharmacol Sci"},{"key":"BF03346679_CR43","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1074\/jbc.M211584200","volume":"278","author":"RA Worthylake","year":"2003","unstructured":"Worthylake RA, Burridge K. RhoA and ROCK promote migration by limiting membrane protrusions. J Biol Chem 2003, 278: 13578\u201384.","journal-title":"J Biol Chem"},{"key":"BF03346679_CR44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/FJC.0b013e31818953d0","volume":"52","author":"T Largiad\u00e8r","year":"2008","unstructured":"Largiad\u00e8r T, Eto M, Payeli SK, et al. Endothelial nitric oxide synthase gene transfer inhibits human smooth muscle cell migration via inhibition of Rho A. J Cardiovasc Pharmacol 2008, 52: 369\u201374.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BF03346679_CR45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","volume":"69","author":"WL Smith","year":"2000","unstructured":"Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69: 145\u201382.","journal-title":"Annu Rev Biochem"},{"key":"BF03346679_CR46","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1074\/jbc.273.6.3551","volume":"273","author":"AR Brasier","year":"1998","unstructured":"Brasier AR, Jamaluddin M, Casola A, Duan W, Shen Q, Garofalo RP. A promoter recruitment mechanism for tumor necrosis factor-alpha-induced interleukin-8 transcription in type II pulmonary epithelial cells. Dependence on nuclear abundance of Rel A, NF-kappaB1, and c-Rel transcription factors. J Biol Chem 1998, 273: 3551\u201361.","journal-title":"J Biol Chem"},{"key":"BF03346679_CR47","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1074\/jbc.274.13.8506","volume":"274","author":"S Montaner","year":"1999","unstructured":"Montaner S, Perona R, Saniger L, Lacal JC. Activation of serum response factor by RhoA is mediated by the nuclear factor-kappaB and C\/EBP transcription factors. J Biol Chem 1999, 274: 8506\u201315.","journal-title":"J Biol Chem"},{"key":"BF03346679_CR48","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.LAB.0000081388.40145.65","volume":"83","author":"GE Steiner","year":"2003","unstructured":"Steiner GE, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003, 83: 1131\u201346.","journal-title":"Lab Invest"},{"key":"BF03346679_CR49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jss.2007.02.038","volume":"142","author":"A Fichera","year":"2007","unstructured":"Fichera A, Little N, Dougherty U, et al. A vitamin D analogue inhibits colonic carcinogenesis in the AOM\/DSS model. J Surg Res 2007, 142: 239\u201345.","journal-title":"J Surg Res"},{"key":"BF03346679_CR50","first-page":"2525","volume":"26","author":"J Moreno","year":"2006","unstructured":"Moreno J, Krishnan AV, Peehl DM, Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 2006, 26: 2525\u201330.","journal-title":"Anticancer Res"},{"key":"BF03346679_CR51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/molehr\/gal113","volume":"13","author":"S Shimizu","year":"2007","unstructured":"Shimizu S, Tahara M, Ogata S, et al. Involvement of nuclear factor-kB activation through RhoA\/Rho-kinase pathway in LPS-induced IL-8 production in human cervical stromal cells. Mol Hum Reprod 2007, 13: 181\u20137.","journal-title":"Mol Hum Reprod"},{"key":"BF03346679_CR52","doi-asserted-by":"crossref","first-page":"E315","DOI":"10.1152\/ajpendo.00590.2005","volume":"291","author":"J Sun","year":"2006","unstructured":"Sun J, Kong J, Duan Y, et al. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 2006, 291: E315\u201322.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"BF03346679_CR53","doi-asserted-by":"crossref","first-page":"49378","DOI":"10.1074\/jbc.M308448200","volume":"278","author":"X Dong","year":"2003","unstructured":"Dong X, Craig T, Xing N, et al. Direct transcriptional regulation of RelB by 1 alpha,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J Biol Chem 2003, 278: 49378\u201385.","journal-title":"J Biol Chem"},{"key":"BF03346679_CR54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4049\/jimmunol.178.1.145","volume":"178","author":"G Penna","year":"2007","unstructured":"Penna G, Amuchastegui S, Giarratana N, et al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 2007, 178: 145\u201353.","journal-title":"J Immunol"},{"key":"BF03346679_CR55","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.4049\/jimmunol.173.4.2280","volume":"173","author":"N Giarratana","year":"2004","unstructured":"Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 2004, 173: 2280\u20137.","journal-title":"J Immunol"},{"key":"BF03346679_CR56","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/carcin\/bgl041","volume":"27","author":"BY Bao","year":"2006","unstructured":"Bao BY, Yao J, Lee YF. 1 alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006, 27: 1883\u201393.","journal-title":"Carcinogenesis"},{"key":"BF03346679_CR57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1432-1033.1997.00063.x","volume":"250","author":"H Harant","year":"1997","unstructured":"Harant H, Andrew PJ, ReddyGS, Foglar E, Lindley IJ. 1alpha,25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-kappaB-mediated interleukin-8 gene expression. Eur J Biochem 1997, 250: 63\u201371.","journal-title":"Eur J Biochem"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03346679.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03346679\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03346679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T05:25:02Z","timestamp":1746163502000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03346679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,12]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["BF03346679"],"URL":"https:\/\/doi.org\/10.1007\/bf03346679","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,12]]}}}